Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Golden, Joseph W ^a   Hammerbeck, Christopher D ^a   Mucker, Eric M ^a   Brocato, Rebecca L ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARENAVIRUS; DISEASE CARRIER; DISEASE COURSE; DISEASE PREDISPOSITION; EXPERIMENTAL INFECTION; GUINEA PIG; HAMSTER; HANTAVIRUS; HEMORRHAGIC FEVER; HUMAN; NONHUMAN; PERSISTENT INFECTION; PICHINDE VIRUS; REVIEW; VIRUS PATHOGENESIS; VIRUS STRAIN; ANIMAL; ANIMAL MODEL; HANTAVIRUS INFECTIONS; HEMORRHAGIC FEVERS, VIRAL; PATHOGENICITY; PATHOLOGY; RODENT; VIROLOGY;

ANIMALIA; RODENTIA;

ANIMALS; ARENAVIRUS; DISEASE RESERVOIRS; HANTAVIRUS; HANTAVIRUS INFECTIONS; HEMORRHAGIC FEVERS, VIRAL; HUMANS; MODELS, ANIMAL; RODENTIA;

EID: 84938632990     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/793257     Document Type: Review

References (302)

1. B. G.Meerburg, G. R. Singleton, and A. Kijlstra, Rodent-borne diseases and their risks for public health Critical Reviews in Microbiology, vol. 35, no. 3, pp. 221-270, 2009.
2. M. Goeijenbier, J. Wagenaar, M. Goris et al., Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable-epidemiology, diagnostics and treatment Critical Reviews in Microbiology, vol. 39, no. 1, pp. 26-42, 2013.
3. M. R.Hilleman, Overview: cause and prevention in biowarfare and bioterrorism Vaccine, vol. 20, no. 25-26, pp. 3055-3067, 2002.
4. S. Paessler and D. H. Walker, Pathogenesis of the viral hemorrhagic fevers Annual Review of Pathology: Mechanisms of Disease, vol. 8, pp. 411-440, 2013.
5. D. R. Smith, M. R. Holbrook, and B. B. Gowen, Animalmodels of viral hemorrhagic fever Antiviral Research, vol. 112, pp. 59-79, 2014.
6. C. J. Peters, P. B. Jahrling, C. T. Liu, R. H. Kenyon, K. T.McKee Jr., and J. G. B. Oro, Experimental studies of arenaviral hemorrhagic fevers Current Topics in Microbiology and Immunology, vol. 134, pp. 5-68, 1987.
7. M.-L. Moraz and S. Kunz, Pathogenesis of arenavirus hemorrhagic fevers Expert ReviewofAnti-InfectiveTherapy, vol. 9, no. 1, pp. 49-59, 2011.
8. M. J. Buchmeier, J. C.De La Torre, andC. J.Peters, Arenaviridae: the viruses and their replication in Fields Virology, D. M. Knipe and P. M. Howley, Eds., vol. 2, pp. 1283-1303, Lippincott Williams andWilkins, Philadelphia, Pa, USA, 5th edition, 2013.
9. C. Armstrong and R. D. Lillie, Experimental lymphocytic chriomeningitis of monkeys and mice produced by a virus encountered in studies of the 1993 St. Louis encephalitis epidemic Public Health Reports (1896-1970), vol. 49, no. 35, pp. 1019-1027, 1934.
10. J. E. Smadel, R. H. Green, R. M. Paltauf, and T. A. Gonzales, Lymphocytic choriomeningitis: two human fatalities following an unusual febrile illness Experimental Biology and Medicine, vol. 49, no. 4, pp. 683-686, 1942.
11. J. B. McCormick and S. P. Fisher-Hoch, Lassa fever Current Topics in Microbiology and Immunology, vol. 262, pp. 75-109, 2002.
12. D. Safronetz, N. Sogoba, J. E. Lopez et al., Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali PLoS Neglected Tropical Diseases, vol. 7, no. 12, Article ID e2582, 2013.
13. M. D. Bowen, C. J. Peters, and S. T. Nichol, The phylogeny of NewWorld (Tacaribe complex) arenaviruses Virology, vol. 219, no. 1, pp. 285-290, 1996.
14. R. N. Charrel and X. de Lamballerie, Arenaviruses other than Lassa virus Antiviral Research, vol. 57,no. 1-2, pp. 89-100, 2003.
15. J. T. Paweska, N. H. Sewlall, T. G. Ksiazek et al., Nosocomial outbreak of novel arenavirus infection, southern Africa Emerging Infectious Diseases, vol. 15, no. 10, pp. 1598-1602, 2009.
16. S. Delgado, B. R. Erickson, R. Agudo et al., Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia PLoS Pathogens, vol. 4, no. 4, Article ID e1000047, 2008.
17. Centers for Disease Control and Prevention (CDC), Fatal illnesses associated with a New World arenavirus-California, 1999-2000 The Journal of the American Medical Association, vol. 284, pp. 1237-1238, 2000.
18. A. S. Parodi, H. R. Rugiero, D. J. Greenway et al., Isolation of the Junin virus (epidemic hemorrhagic fever) from the mites of the epidemic area (Echinolaelaps echidninus, Barlese) Prensa Medica Argentina, vol. 46, pp. 2242-2244, 1959.
19. K. M. Johnson, R. B. Mackenzie, P. A. Webb, and M. L. Kuns, Chronic infection of rodents by Machupo virus Science, vol. 150, no. 3703, pp. 1618-1619, 1965.
20. J. Salazar-Bravo, L. A. Ruedas, and T. L. Yates, Mammalian reservoirs of arenaviruses Current Topics in Microbiology and Immunology, vol. 262, pp. 25-63, 2002.
21. T. P.Monath, Lassa fever: reviewof epidemiology and epizootiology Bulletin of theWorldHealthOrganization, vol. 52,no. 4-5, pp. 577-592, 1975.
22. M. L. Kuns, Epidemiology of Machupo virus infection. II. Ecological and control studies of hemorrhagic fever The American Journal of Tropical Medicine and Hygiene, vol. 14, no. 5, pp. 813-816, 1965.
23. W. G.Downs, C. R. Anderson, L. Spence, T. H. Aitken, and A. H. Greenhall, Tacaribe virus, a new agent isolated from Artibeus bats and mosquitoes in Trinidad, West Indies The American Journal of Tropical Medicine and Hygiene, vol. 12, pp. 640-646, 1963.
24. A. Cogswell-Hawkinson, R. Bowen, S. James et al., Tacaribe virus causes fatal infection of an ostensible reservoir host, the Jamaican fruit bat Journal of Virology, vol. 86, no. 10, pp. 5791-5799, 2012.
25. C. J. Peters, Human infection with arenaviruses in the Americas Current Topics in Microbiology and Immunology, vol. 262, pp. 65-74, 2002.
26. S. P. Fisher-Hoch, O. Tomori, A. Nasidi et al., Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice The BritishMedical Journal, vol. 311, no. 7009, pp. 857-859, 1995.
27. B. J. Stinebaugh, F. X. Schloeder, K. M. Johnson, R. B. Mackenzie, G. Entwisle, and E. de Alba, Bolivian hemorrhagic fever. A report of four cases The American Journal ofMedicine, vol. 40, no. 2, pp. 217-230, 1966.
28. N. E. Yun and D. H. Walker, Pathogenesis of Lassa fever Viruses, vol. 4, no. 10, pp. 2031-2048, 2012.
29. S. C. Levis, M. C. Saavedra, C. Ceccoli et al., Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever Journal of Interferon Research, vol. 5, no. 3, pp. 383-389, 1985.
30. M. V. Heller,M. C. Saavedra, R. Falcoff, J. I.Maiztegui, and F. C. Molinas, Increased tumor necrosis factor-levels in Argentine hemorrhagic fever The Journal of Infectious Diseases, vol. 166, no. 5, pp. 1203-1204, 1992.
31. Centers for Disease Control and Prevention (CDC), Imported Lassa fever-New Jersey, 2004 Morbidity and MortalityWeekly Report, vol. 53, no. 38, pp. 894-897, 2004.
32. B.Elsner, E. Schwarz, O. G.Mando, J.Maiztegui, andA.Vilches, Pathology of 12 fatal cases ofArgentine hemorrhagic fever The American Journal of Tropical Medicine andHygiene, vol. 22, no. 2, pp. 229-236, 1973.
33. J. I. Maiztegui, Clinical and epidemiological patterns of Argentine haemorrhagic fever Bulletin of the World Health Organization, vol. 52, no. 4-5, pp. 567-575, 1975.
34. J. I.Maiztegui,K.T.McKee Jr., J. G. B. Oro et al., Protective efficacy of a live attenuated vaccine against argentine hemorrhagic fever Journal of Infectious Diseases, vol. 177, no. 2, pp. 277-283, 1998.
35. J. I.Maiztegui, N. J. Fernandez, and A. J. de Damilano, Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome The Lancet, vol. 314, no. 8154, pp. 1216-1217, 1979.
36. J. B. McCormick, I. J. King, P. A. Webb et al., Lassa fever: effective therapy with ribavirin The New England Journal of Medicine, vol. 314, no. 1, pp. 20-26, 1986.
37. K.T.McKee Jr., J.W. Huggins, C. J. Trahan, and B. G. Mahlandt, Ribavirin prophylaxis and therapy for experimental Argentine hemorrhagic fever Antimicrobial Agents and Chemotherapy, vol. 32, no. 9, pp. 1304-1309, 1988.
38. D. A. Enria, A. M. Briggiler, and Z. ͆anchez, Treatment of Argentine hemorrhagic fever Antiviral Research, vol. 78, no. 1, pp. 132-139, 2008.
39. C. Schmaljohn and S. T. Nichol, Bunyaviridae Fields Virology, LippincottWilliamsandWilkins, Philadelphia, Pa,USA, pp. 1741-1789, 2006.
40. K. M. Jäaskelainen, P. Kaukinen, E. S.Minskaya et al., Tula and Puumala hantavirus NSs ORFs are functional and the products inhibit activation of the interferon-beta promoter Journal of Medical Virology, vol. 79, no. 10, pp. 1527-1536, 2007.
41. A. Billecocq, M. Spiegel, P. Vialat et al., NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription Journal of Virology, vol. 78, no. 18, pp. 9798-9806, 2004.
42. G.Blakqori, S. Delhaye,M. Habjan et al., LaCrosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts Journal of Virology, vol. 81, no. 10, pp. 4991-4999, 2007.
43. V. Cimica, N. A. Dalrymple, E. Roth, A. Nasonov, and E. R. Mackow, An innate immunity-regulating virulence determinant is uniquely encoded by the Andes virus nucleocapsid protein mBio, vol. 5, no. 1, 2014.
44. J. Clement, P. Maes, K. Lagrou, M. van Ranst, and N. Lameire, A unifying hypothesis and a single name for a complex globally emerging infection: Hantavirus disease European Journal of ClinicalMicrobiologyandInfectious Diseases, vol. 31, no. 1, pp. 1-5, 2012.
45. I. Gavrilovskaya, E. Gorbunova, V.Matthys, N. Dalrymple, and E. MacKow, The role of the endothelium in HPS pathogenesis and potential therapeutic approaches Advances in Virology, vol. 2012, Article ID467059, 12 pages, 2012.
46. M. Liang, M. Guttieri, A. Lundkvist, and C. Schmaljohn, Baculovirus expression of a human G2-specific, neutralizing IgG monoclonal antibody to Puumala virus Virology, vol. 235, no. 2, pp. 252-260, 1997.
47. S. R. Zaki, P. W. Greer, L. M. Coffield et al., Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease The American Journal of Pathology, vol. 146, no. 3, pp. 552-579, 1995.
48. J. A. Lednicky, Hantaviruses. A short review Archives of PathologyandLaboratoryMedicine, vol. 127, no. 1,pp. 30-35, 2003.
49. B. Settergren, Nephropathia epidemica (hemorrhagic fever with renal syndrome) in Scandinavia Reviews of Infectious Diseases, vol. 13, no. 4, pp. 736-744, 1991.
50. C. B. Zeimes, S. Quoilin, H. Henttonen et al., Landscape and regional environmental analysis of the spatial distribution of hantavirus human cases in Europe Frontiers in Public Health, vol. 3, article 54, 2015.
51. T. F. Tsai, S. P. Bauer, D. R. Sasso et al., Serological and virological evidence of a Hantaan virus-related enzootic in the United States The Journal of Infectious Diseases, vol. 152, no. 1, pp. 126-136, 1985.
52. R.W.Cross,B.Waffa, A. Freemanet al., Oldworldhantaviruses in rodents in New Orleans, Louisiana The American Journal of TropicalMedicine and Hygiene, vol. 90, no. 5, pp. 897-901, 2014.
53. C. Schmaljohn and B. Hjelle, Hantaviruses: a global disease problem Emerging Infectious Diseases, vol. 3, no. 2, pp. 95-104, 1997.
54. C. B. Jonsson, L. T. M. Figueiredo, and O. Vapalahti, A global perspective on hantavirus ecology, epidemiology, and disease Clinical Microbiology Reviews, vol. 23, no. 2, pp. 412-441, 2010.
55. H. J. Kang, M. Y. Kosoy, S. K. Shrestha et al., Genetic diversity of Thottapalayam virus, a hantavirus harbored by the Asian house shrew (Suncus murinus) inNepal The American Journal of Tropical Medicine and Hygiene, vol. 85, no. 3, pp. 540-545, 2011.
56. H. J. Kang, S. N. Bennett, L. Sumibcay et al., Evolutionary insights froma genetically divergent hantavirus harbored by the European common mole (Talpa europaea) PLoS ONE, vol. 4, no. 7, Article IDe6149, 2009.
57. S. Weiss, P. T. Witkowski, B. Auste et al., Hantavirus in bat, Sierra Leone Emerging Infectious Diseases, vol. 18, no. 1, pp. 159-161, 2012.
58. E. R. Kallio, J. Klingstrom, E. Gustafsson et al., Prolonged survival of Puumala hantavirus outside the host: evidence for indirect transmission via the environment The Journal of General Virology, vol. 87, no. 8, pp. 2127-2134, 2006.
59. O. Vapalahti, J. Mustonen, A. Lundkvist, H. Henttonen, A. Plyusnin, and A. Vaheri, Hantavirus infections in Europe The Lancet Infectious Diseases, vol. 3, no. 10, pp. 653-661, 2003.
60. C. Martinez-Valdebenito, M. Calvo, C. Vial et al., Personto-person household and nosocomial transmission of Andes hantavirus, Southern Chile, 2011 Emerging Infectious Diseases, vol. 20, no. 10, pp. 1629-1636, 2014.
61. J. J. Smith and S. C. St. Jeor, Three-week incubation period for hantavirus infection The Pediatric Infectious Disease Journal, vol. 23, no. 10, pp. 974-975, 2004.
62. J.W.Hooper, A.M. Ferro, and V.Wahl-Jensen, Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus Journal of Virology, vol. 82, no. 3, pp. 1332-1338, 2008.
63. C. Schmaljohn, Vaccines for hantaviruses Vaccine, vol. 27, supplement 4, pp. D61-D64, 2009.
64. T. Manigold and P. Vial, Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology Swiss MedicalWeekly, vol. 144, Article IDw13937, 2014.
65. J. S. Duchin, F. T. Koster, C. J. Peters et al., Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease The New England Journal of Medicine, vol. 330, no. 14, pp. 949-955, 1994.
66. P. J. Padula, S. B. Colavecchia, V. P. Martinez et al., Genetic diversity, distribution, and serological features of hantavirus infection in five countries in South America Journal of Clinical Microbiology, vol. 38, no. 8, pp. 3029-3035, 2000.
67. M. Bharadwaj, R. Nofchissey, D. Goade, F. Koster, and B. Hjelle, Humoral immune responses in the hantavirus cardiopulmonary syndrome The Journal of Infectious Diseases, vol. 182, no. 1, pp. 43-48, 2000.
68. M. Mori, A. L. Rothman, I. Kurane et al., High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome The Journal of Infectious Diseases, vol. 179, no. 2, pp. 295-302, 1999.
69. K. B.Nolte, R.M. Feddersen, K. Foucar et al., Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent Human Pathology, vol. 26, no. 1, pp. 110-120, 1995.
70. S.Makela, J.Mustonen, I.Ala-Houhala et al., Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factoralpha( 308) G/A polymorphism The Journal of Infectious Diseases, vol. 186, no. 6, pp. 843-846, 2002.
71. J. Mustonen, J. Partanen, M. Kanerva et al., Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus Kidney International, vol. 49, no. 1, pp. 217-221, 1996.
72. J. Mustonen, J. Partanen, M. Kanerva et al., Association of HLA B27 with benign clinical course of nephropathia epidemica caused by Puumala hantavirus Scandinavian Journal of Immunology, vol. 47, no. 3, pp. 277-279, 1998.
73. E. D. Kilpatrick, M. Terajima, F. T. Koster, M. D. Catalina, J. Cruz, and F. A. Ennis, Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome The Journal of Immunology, vol. 172, no. 5, pp. 3297-3304, 2004.
74. F. A. Ennis, J. Cruz, C. F. Spiropoulou et al., Hantavirus pulmonary syndrome:CD8+ andCD4+ cytotoxic t lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness Virology, vol. 238, no. 2, pp. 380-390, 1997.
75. M. Terajima, D. Hayasaka, K. Maeda, and F. A. Ennis, Immunopathogenesis of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome: do CD8+ T cells trigger capillary leakage in viral hemorrhagic fevers Immunology Letters, vol. 113, no. 2, pp. 117-120, 2007.
76. T. Tuuminen, E. Kekalainen, S. Makela et al., Human CD8+ T cell memory generation in Puumala hantavirus infection occurs after the acute phase and is associated with boosting of EBVspecific CD8+ memory T cells Journal of Immunology, vol. 179, no. 3, pp. 1988-1995, 2007.
77. A. A. Borges, G. M. Campos, M. L. Moreli et al., Hantavirus cardiopulmonary syndrome: immune response and pathogenesis Microbes and Infection, vol. 8, no. 8, pp. 2324-2330, 2006.
78. I. Gavrilovskaya, E. Gorbunova, F. Koster, and E. MacKow, Elevated vegf levels in pulmonary edema fluid and pbmcs from patients with acute hantavirus Pulmonary syndrome Advances in Virology, vol. 2012,Article ID 674360, 8 pages, 2012.
79. L. B. De Guerrero,M. C. Boxaca, and A. S. Parodi, Experimental hemorrhagic fever in Guinea pigs (Juńn virus). Contagion and elimination of the virus Revista de la Asociacion Medica Argentina, vol. 79, no. 6, pp. 271-274, 1965.
80. R. H. Kenyon, D. E. Green, G. A. Eddy, and C. J. Peters, Treatment of Junin virus-infected Guinea pigs with immune serum: development of late neurological disease Journal of Medical Virology, vol. 20, no. 3, pp. 207-218, 1986.
81. R. H. Kenyon, D. E. Green, J. I. Maiztegui, and C. J. Peters, Viral strain dependent differences in experimental Argentine hemorrhagic fever (Junin virus) infection of Guinea pigs Intervirology, vol. 29, no. 3, pp. 133-143, 1988.
82. S. R. Samoilovich, M. A. Calello, R. P. Laguens, and M. C. Weissenbacher, Long-term protection against Argentine hemorrhagic fever in Tacaribe virus infected marmosets: virologic and histopathologic findings Journal of Medical Virology, vol. 24, no. 2, pp. 229-236, 1988.
83. N. E. Yun, N. S. Linde, N. Dziuba et al., Pathogenesis of XJ and Romero strains of Junin virus in two strains of Guinea pigs The American Journal of Tropical Medicine and Hygiene, vol. 79, no. 2, pp. 275-282, 2008.
84. R. H. Kenyon, K. T. McKee Jr., J. I. Maiztegui, D. E. Green, and C. J. Peters, Heterogeneity of Junin virus strains Medical Microbiology and Immunology, vol. 175, no. 2-3, pp. 169-172, 1986.
85. N. A. Candurra, E. B. Damonte, and C. E. Coto, Antigenic relationships between attenuated and pathogenic strains of Junin virus Journal of Medical Virology, vol. 27, no. 2, pp. 145-150, 1989.
86. M. C. Weissenbacher, L. B. de Guerrero, and M. C. Boxaca, Experimental biology and pathogenesis of Junin virus infection in animals and man Bulletin of the World Health Organization, vol. 52, no. 4-5, pp. 507-515, 1975.
87. J. R.Oubina, G. Carballal, C. M. Videla, and P.M.Cossio, The Guinea pig model for Argentine hemorrhagic fever American Journal of TropicalMedicine and Hygiene, vol. 33,no. 6, pp. 1251-1257, 1984.
88. C. B. Dejean, B. L. Ayerra, and A. R. Teyssie, Interferon response in the Guinea pig infected with Junin virus Journal of Medical Virology, vol. 23, no. 1, pp. 83-91, 1987.
89. N. Ĺopez, L. Scolaro, C. Rossi et al., Homologous and heterologous glycoproteins induce protection against Junin virus challenge in Guinea pigs The Journal of General Virology, vol. 81, no. 5, pp. 1273-1281, 2000.
90. A. V. Seregin, N. E. Yun, A. L. Poussard et al., TC83 replicon vectored vaccine provides protection against Junin virus in Guinea pigs Vaccine, vol. 28, no. 30, pp. 4713-4718, 2010.
91. B. Cresta, P. Padula, and Z. M. D. M. Segovia, Biological properties of Junin virus proteins. I. Identification of the immunogenic glycoprotein Intervirology, vol. 13, no. 5, pp. 284-288, 1980.
92. B. B. Gowen, T. L. Juelich, E. J. Sefing et al., Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a Guinea pig model of Argentine hemorrhagic fever PLoS Neglected Tropical Diseases, vol. 7, no. 12, Article IDe2614, 2013.
93. M. Salazar, N. E. Yun, A. L. Poussard et al., Effect of ribavirin on junin virus infection in Guinea pigs Zoonoses and Public Health, vol. 59, no. 4, pp. 278-285, 2012.
94. C. J. Peters, R. W. Kuehne, R. R. Mercado, R. H. le Bow, R. O. Spertzel, and P. A. Webb, Hemorrhagic fever in Cochabamba, Bolivia, 1971 American Journal of Epidemiology, vol. 99, no. 6, pp. 425-433, 1974.
95. M. C. Weissenbacher, C. E. Coto, and M. A. Calello, Crossprotection between Tacaribe complex viruses. Presence of neutralizing antibodies against Junin virus (Argentine hemorrhagic fever) in Guinea pigs infected with Tacaribe virus Intervirology, vol. 6, pp. 42-49, 1975.
96. P. A.Webb, G. Justines, and K. M. Johnson, Infection of wild and laboratory animals with Machupo and Latino viruses Bulletin of the World Health Organization, vol. 52, no. 4-5, pp. 493-499, 1975.
97. T.M. Bell, C. I. Shaia, T. E. Bunton et al., Pathology of experimental machupo virus infection, chicava strain, in cynomolgus macaques (Macaca fascicularis) by intramuscular and aerosol exposure Veterinary Pathology, vol. 52, no. 1, pp. 26-37, 2015.
98. W. C. Hall, T. W. Geisbert, J. W. Huggins, and P. B. Jahrling, Experimental infection of Guinea pigs with Venezuelan hemorrhagic fever virus (Guanarito): a model of human disease The American Journal of TropicalMedicine and Hygiene, vol. 55, no. 1, pp. 81-88, 1996.
99. R. B.Tesh, P. B. Jahrling,R. Salas, and R. E. Shope, Description of Guanarito virus (Arenaviridae: Arenavirus), the etiologic agent of Venezuelan hemorrhagic fever The American Journal of Tropical Medicine and Hygiene, vol. 50, no. 4, pp. 452-459, 1994.
100. H. Wulff and K. M. Johnson, Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa orMarburg virus infections Bulletin of theWorld Health Organization, vol. 57, no. 4, pp. 631-635, 1979.
101. D. Safronetz, J. E. Strong, F. Feldmann et al., A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques The Journal of Infectious Diseases, vol. 207, no. 8, pp. 1316-1327, 2013.
102. P. B. Jahrling, J. D. Frame, S. B. Smith, and M. H. Monson, Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 79, no. 3, pp. 374-379, 1985.
103. S. F. Emonet, A.V. Seregin,N. E. Yun et al., Rescue fromcloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuatedCandid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease Journal of Virology, vol. 85, no. 4, pp. 1473-1483, 2011.
104. M. I. Berria, L. F. Gutman Frugone, R. Girola, and J. G. Barrera Oro, Immunological studies with Junin virus. I. Formation of antibodies in Guinea pigs inoculated with live viruses Medicina, vol. 27, no. 2, pp. 93-98, 1967.
105. A. S. Parodi, D. J. Greenway, H. R. Rugiero et al., Concerning the epidemic outbreak in Junin El Da Medico, vol. 30, no. 62, pp. 2300-2301, 1958.
106. K. T. McKee Jr., B. G. Mahlandt, J. I. Maiztegui, G. A. Eddy, and C. J. Peters, Experimental Argentine hemorrhagic fever in rhesus macaques: viral strain-dependent clinical response The Journal of Infectious Diseases, vol. 152, no. 1, pp. 218-221, 1985.
107. K. T. McKee Jr., J. G. Oro, A. I. Kuehne, J. A. Spisso, and B. G. Mahlandt, Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques Intervirology, vol. 34, no. 3, pp. 154-163, 1992.
108. B. H. Bird, K. A. Dodd, B. R. Erickson et al., Severe hemorrhagic fever in strain 13/N Guinea pigs infected with Lujo virus PLoS Neglected Tropical Diseases, vol. 6, no. 8, Article ID e1801, 2012.
109. P. B. Jahrling, S. Smith, R. A. Hesse, and J. B. Rhoderick, Pathogenesis of Lassa virus infection in Guinea pigs Infection and Immunity, vol. 37, no. 2, pp. 771-778, 1982.
110. D. H. Walker, H. Wulff, J. V. Lange, and F. A. Murphy, Comparative pathology of Lassa virus infection in monkeys, Guinea pigs, and Mastomys natalensis Bulletin of the World Health Organization, vol. 52, no. 4-5, pp. 523-534, 1975.
111. P. B. Jahrling, R. A. Hesse, G. A. Eddy, K. M. Johnson, R. T. Callis, and E. L. Stephen, Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin The Journal of Infectious Diseases, vol. 141, no. 5, pp. 580-589, 1980.
112. R. T. Callis, P. B. Jahrling, and A. DePaoli, Pathology of Lassa virus infection in the rhesus monkey The American Journal of Tropical Medicine and Hygiene, vol. 31, no. 5, pp. 1038-1045, 1982.
113. J. V. Lange, S.W.Mitchell, J. B.McCormick, D. H.Walker, B. L. Evatt, and R. R. Ramsey, Kinetic study of platelets and fibrinogen in Lassa virus-infectedmonkeys and early pathologic events in Mopeia virus-infected monkeys The American Journal of TropicalMedicine andHygiene, vol. 34,no. 5, pp. 999-1007, 1985.
114. S. P. Fisher-Hoch, S. W. Mitchell, D. R. Sasso, J. V. Lange, R. Ramsey, and J. B.McCormick, Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever The Journal of Infectious Diseases, vol. 155, no. 3, pp. 465-474, 1987.
115. L. E. Hensley, M. A. Smith, J. B. Geisbert et al., Pathogenesis of lassa fever in cynomolgus macaques Virology Journal, vol. 8, article 205, 2011.
116. E. H. Stephenson, E. W. Larson, and J. W. Dominik, Effect of environmental factors on aerosol-induced Lassa virus infection Journal of Medical Virology, vol. 14, no. 4, pp. 295-303, 1984.
117. S. Malhotra, J. Y. Yen, A. N. Honko et al., Transcriptional profiling of the circulating immune response to lassa virus in an aerosolmodel of exposure PLoSNeglectedTropical Diseases, vol. 7, no. 4, Article ID e2171, 2013.
118. R. Carrion Jr., K. Brasky, K. Mansfield et al., Lassa virus infection in experimentally infectedmarmosets: liver pathology and immunophenotypic alterations in target tissues Journal of Virology, vol. 81, no. 12, pp. 6482-6490, 2007.
119. I. S. Lukashevich, R. Carrion Jr., M. S. Salvato et al., Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates Vaccine, vol. 26, no. 41, pp. 5246-5254, 2008.
120. A. L. Rasmussen, N. Tchitchek, D. Safronetz et al., Delayed inflammatory and cell death responses are associated with reduced pathogenicity in lujo virus-infected cynomolgus macaques Journal of Virology, vol. 89, no. 5, pp. 2543-2552, 2015.
121. C. G. Albarĩno, B. H. Bird, A. K. Chakrabarti et al., The major determinant of attenuation in mice of the candid1 vaccine for argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain Journal of Virology, vol. 85, no. 19, pp. 10404-10408, 2011.
122. O. A. Kolokoltsova, N. E. Yun, A. L. Poussard et al., Mice lacking alpha/beta and gamma interferon receptors are susceptible to Junin virus infection Journal of Virology, vol. 84, no. 24, pp. 13063-13067, 2010.
123. D. E. Green, B. G.Mahlandt, andK. T.McKee Jr., Experimental Argentine hemorrhagic fever in rhesusmacaques: virus-specific variations in pathology Journal ofMedical Virology, vol. 22, no. 2, pp. 113-133, 1987.
124. K. T.McKee Jr.,B.G.Mahlandt, J. I.Maiztegui, D. E. Green, and C. J. Peters, Virus-specific factors in experimental Argentine hemorrhagic fever in rhesus macaques Journal of Medical Virology, vol. 22, no. 2, pp. 99-111, 1987.
125. R. H. Kenyon, K. T. McKee Jr., P. M. Zack et al., Aerosol infection of rhesus macaques with Junin virus Intervirology, vol. 33, no. 1, pp. 23-31, 1992.
126. K. T. McKee Jr., J. G. B. Oro, A. I. Kuehne, J. A. Spisso, and B. G. Mahlandt, Safety and immunogenicity of a liveattenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques The American Journal of Tropical Medicine and Hygiene, vol. 48, no. 3, pp. 403-411, 1993.
127. M. C. Weissenbacher, M. A. Calello, O. J. Colillas, S. N. Rondinone, and M. J. Frigerio, Argentine hemorrhagic fever: a primate model Intervirology, vol. 11, no. 6, pp. 363-365, 1979.
128. M. J. Frigerio, S.N.Rondinone,M.A.Callelo,E.R.Paradisi, and M. C.Weissenbacher, Junin virus infection of Calithrix jacchus: haematological findings ActaVirologica, vol. 26,no. 4, pp. 270-278, 1982.
129. F. C. Molinas, E. Giavedoni, M. J. Frigerio, M. A. Calello, J. A. Barcat, and M. C. Weissenbacher, Alteration of blood coagulation and complement system in neotropical primates infected with junin virus Journal of Medical Virology, vol. 12, no. 4, pp. 281-292, 1983.
130. P. H. Gonzalez, R. P. Laguens, M. J. Frigerio, M. A. Calello, and M. C. Weissenbacher, Junin virus infection of Callithrix jacchus: pathologic features The American Journal of Tropical Medicine and Hygiene, vol. 32, no. 2, pp. 417-423, 1983.
131. A. D. Vitullo and M. S. Merani, Is vertical transmission sufficient to maintain Junin virus in nature The Journal of General Virology, vol. 69, pp. 1437-1440, 1988.
132. A. D. Vitullo and M. S. Merani, Vertical transmission of Junin virus in experimentally infected adult Calomys musculinus Intervirology, vol. 31, no. 6, pp. 339-344, 1990.
133. J. E. Childs and C. J. Peter, Ecology and epidemiology of arenaviruses and their hosts in The Arenaviridae, M. Salvato, Ed., pp. 331-384, Plenum Press, New York, NY, USA, 1993.
134. L. E. Alche and C. E. Coto, Differentiation of Junin virus and antigenic variants isolated in vivo by kinetic neutralization assays The Journal of General Virology, vol. 69, no. 8, pp. 2123-2127, 1988.
135. M. Patterson, A. Seregin, C. Huang et al., Rescue of a recombinant Machupo virus from cloned cDNAs and in vivo characterization in interferon (/) receptor double knockout mice Journal of Virology, vol. 88, no. 4, pp. 1914-1923, 2014.
136. S. B. Bradfute, K. S. Stuthman, A. C. Shurtleff, and S. Bavari, A STAT-1 knockout mouse model for Machupo virus pathogenesis Virology Journal, vol. 8, article 300, 2011.
137. G. A. Eddy, S. K. Scott, F. S. Wagner, and O. M. Brand, Pathogenesis of Machupo virus infection in primates Bulletin of the World Health Organization, vol. 52, no. 4-5, pp. 517-521, 1975.
138. M.D.Kastello, G. A. Eddy, andR.W. Kuehne, Arhesusmonkey model for the study of Bolivian hemorrhagic fever The Journal of Infectious Diseases, vol. 133, no. 1, pp. 57-62, 1976.
139. C. G. McLeod, J. L. Stookey, G. A. Eddy, and S. K. Scott, Pathology of chronic bolivian hemorrhagic fever in the rhesus monkey The American Journal of Pathology, vol. 84, no. 2, pp. 211-224, 1976.
140. S. K. Scott, R. L. Hickman, C.M. Lang,G.A.Eddy, D. E. Hilmas, and R.O. Spertzel, Studies of the coagulation systemand blood pressure during experimental Bolivian hemorrhagic fever in rhesus monkeys The American Journal of Tropical Medicine and Hygiene, vol. 27, no. 6, pp. 1232-1239, 1978.
141. G. Justines and K. M. Johnson, Immune tolerance in Calomys callosus infectedwithMachupovirus Nature, vol. 222, no. 5198, pp. 1090-1091, 1969.
142. M. J. Buchmeier andW. E. Rawls, Variation between strains of hamsters in the lethality of Pichinde virus infections Infection and Immunity, vol. 16, no. 2, pp. 413-421, 1977.
143. D. F. Smee, J. Gilbert, J. A. Leonhardt, B. B. Barnett, J. H. Huggins, and R. W. Sidwell, Treatment of lethal pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen Antiviral Research, vol. 20, no. 1, pp. 57-70, 1993.
144. P. B. Jahrling, R. A. Hesse, J. B. Rhoderick, M. A. Elwell, and J. B. Moe, Pathogenesis of a pichinde virus strain adapted to produce lethal infections in Guinea pigs Infection and Immunity, vol. 32, no. 2, pp. 872-880, 1981.
145. J. Munoz, Comparison between Hartley and strain 13 Guinea pigs-antibody production and delayed hypersensitivity The Journal of Immunology, vol. 99, no. 1, pp. 31-39, 1967.
146. M. Patterson, T. Koma, A. Seregin et al., A substitution in the transmembrane region of the glycoprotein leads to an unstable attenuation of machupo virus Journal of Virology, vol. 88, no. 18, pp. 10995-10999, 2014.
147. N. E. Yun, A. L. Poussard, A. V. Seregin et al., Functional interferon system is required for clearance of lassa virus Journal of Virology, vol. 86, no. 6, pp. 3389-3392, 2012.
148. T. Rieger, D. Merkler, and S. Gunther, Infection of type I interferon receptor-deficient mice with various old world arenaviruses: a model for studying virulence and host species barriers PLoS ONE, vol. 8, no. 8,Article ID e72290, 2013.
149. N. E. Yun, A. V. Seregin, D. H. Walker et al., Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus Journal of Virology, vol. 87, no. 19, pp. 10908-10911, 2013.
150. L. Flatz, T. Rieger, D.Merkler et al., T cell-dependence of lassa fever pathogenesis PLoS Pathogens, vol. 6, no. 3, Article ID e1000836, 2010.
151. J. Abraham, J. A. Kwong, C. G. Albarino et al., Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic new world clade B arenaviruses PLoS Pathogens, vol. 5, no. 4, Article IDe1000358, 2009.
152. S. P. Fisher-Hoch and J. B. McCormick, Pathophysiology and treatment of Lassa fever Current Topics in Microbiology and Immunology, vol. 134, pp. 231-239, 1987.
153. M. P. Kiley, J.V. Lange, and K.M. Johnson, Protection of rhesus monkeys fromLassa virus by immunisation with closely related Arenavirus The Lancet, vol. 314, no. 8145, p. 738, 1979.
154. S. P. Fisher-Hoch, J. B. McCormick, D. Auperin et al., Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene Proceedings of the National Academy of Sciences of theUnited States ofAmerica, vol. 86,no. 1, pp. 317-321, 1989.
155. S. P. Fisher-Hoch, L. Hutwagner, B. Brown, and J. B. McCormick, Effective vaccine for Lassa fever Journal of Virology, vol. 74, no. 15, pp. 6777-6783, 2000.
156. J. B. McCormick, S. W. Mitchell, M. P. Kiley, S. Ruo, and S. P. Fisher-Hoch, Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys Journal of Medical Virology, vol. 37, no. 1, pp. 1-7, 1992.
157. P. B. Jahrling and C. J. Peters, Passive antibody therapy of lassa fever in cynomolgus monkeys: importance of neutralizing antibody and lassa virus strain Infection and Immunity, vol. 44, no. 2, pp. 528-533, 1984.
158. P. B. Jahrling, C. J. Peters, and E. L. Stephen, Enhanced treatment of lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys The Journal of Infectious Diseases, vol. 149, no. 3, pp. 420-427, 1984.
159. E. L. Stephen and P. B. Jahrling, Experimental Lassa fever virus infection successfully treated with ribavirin The Lancet, vol. 313, no. 8110, pp. 268-269, 1979.
160. S. Baize, P.Marianneau, P. Loth et al., Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgusmonkeys Journal of Virology, vol. 83, no. 11, pp. 5890-5903, 2009.
161. M. C. Weissenbacher, C. E. Coto, M. A. Calello, S. N. Rondinone, E. B. Damonte, and M. J. Frigerio, Cross-protection in nonhuman primates against Argentine hemorrhagic fever Infection and Immunity, vol. 35, no. 2, pp. 425-430, 1982.
162. M.M. Avila,M. J. Frigerio, E. L.Weber et al., Attenuated Junin virus infection in Callithrix jacchus Journal ofMedicalVirology, vol. 15, no. 1, pp. 93-100, 1985.
163. M. M. Avila, S. R. Samoilovich, and R. P. Laguens, Protection of Junin virus-infected marmosets by passive administration of immune serum: association with late neurologic signs Journal of Medical Virology, vol. 21, no. 1, pp. 67-74, 1987.
164. M. C. Weissenbacher, M. A. Calello, M. S. Merani, J. B. McCormick, and M. Rodriguez, Therapeutic effect of the antiviral agent Ribavirin in Junin virus infection of primates Journal of Medical Virology, vol. 20, no. 3, pp. 261-267, 1986.
165. M. C. Weissenbacher, M. M. Avila, M. A. Calello, M. S. Merani, J. B. McCormick, and M. Rodriguez, Effect of Ribavirin and immune serum on Junin virus-infected primates Medical Microbiology and Immunology, vol. 175, no. 2-3, pp. 183-186, 1986.
166. A. A. Evseev, V. I. Dvoretskaia, G. V. Bogatikov, V. A. Pshenichnov, and R. M.Mustafin, Experimental Lassa fever in hamadryas baboons Voprosy Virusologii, vol. 36, pp. 150-152, 1991.
167. F. S. Wagner, G. A. Eddy, andO.M. Brand, The African green monkey as an alternate primate host for studying Machupo virus infection The American Journal of Tropical Medicine and Hygiene, vol. 26, no. 1, pp. 159-162, 1977.
168. C. G. McLeod Jr., J. L. Stookey, J. D. White, G. A. Eddy, and G. A. Fry, Pathology of Bolivian hemorrhagic fever in theAfrican green monkey The American Journal of Tropical Medicine and Hygiene, vol. 27, no. 4, pp. 822-826, 1978.
169. V. I. Dvoretskaya, G. V. Bogatikov, V. A. Pshenichnov, and A. A. Evseev The therapeutic efficacy of ribamydil and virasol in experimental Lassa fever in monkeys Voprosy Virusologii, vol. 36 1, 55-57 1991
170. V. P. KrasnianskѤ, N. V. Potryvaeva, I. V. Borisevich, V. N. Gradoboev, T. P. Pashanina, and V. A. Pshenichnov, A trial to produce an inactivated Lassa fever vaccine VoprosyVirusologii, vol. 38, no. 6, pp. 276-279, 1993.
171. R. Carrion Jr. and J. L. Patterson, An animal model that reflects human disease: the common marmoset (Callithrix jacchus) Current Opinion in Virology, vol. 2, no. 3, pp. 357-362, 2012.
172. H. Trapido and C. Sanmartn, Pichinde virus, a new virus of the Tacaribe group from Colombia The American Journal of Tropical Medicine and Hygiene, vol. 20, no. 4, pp. 631-641, 1971.
173. K. E. Wright, K. L. Rosenthal, and W. E. Rawls, Association of reduced interleukin-2 production with genetic susceptibility to Pichinde virus in inbred strains of hamsters Archives of Virology, vol. 92, no. 3-4, pp. 197-209, 1987.
174. B. B.Gowen,D. L. Barnard,D. F. Smee et al., Interferonalfacon-1 protects hamsters from lethal Pichinde virus infection AntimicrobialAgents and Chemotherapy, vol. 49,no. 6, pp.2378-2386, 2005.
175. Y. Liang, S. Lan, andH.Ly, Molecular determinantsofpichinde virus infection of Guinea pigs-a small animal model systemfor arenaviral hemorrhagic fevers Annals of theNewYork Academy of Sciences, vol. 1171, no. 1, pp. E65-E74, 2009.
176. H. Ebihara, K. Yoshimatsu, M. Ogino et al., Pathogenicity of Hantaan virus in newborn mice: genetic reassortant study demonstrating that a single amino acid change in glycoprotein G1 is related to virulence Journal of Virology, vol. 74, no. 19, pp. 9245-9255, 2000.
177. G. R. Kim and K. T. McKee Jr., Pathogenesis of Hantaan virus infection in suckling mice: clinical, virologic, and serologic observations The American Journal of Tropical Medicine and Hygiene, vol. 34, no. 2, pp. 388-395, 1985.
178. K. T. McKee Jr.,G. R. Kim,D. E.Green, and C. J. Peters, Hantaan virus infection in suckling mice: virologic and pathologic correlates Journal ofMedical Virology, vol. 17, no. 2, pp. 107-117, 1985.
179. Y. C. Yoo, K. Yoshimatsu, R. Yoshida, M. Tamura, I. Azuma, and J. Arikawa, Comparison of virulence between Seoul virus strain SR-11 and Hantaan virus strain 76-118 of hantaviruses in newborn mice Microbiology and Immunology, vol. 37, no. 7, pp. 557-562, 1993.
180. J. W. Huggins, G. R. Kim, O. M. Brand, and K. T. McKee Jr., Ribavirin therapy for Hantaan virus infection in suckling mice The Journal of Infectious Diseases, vol. 153, no. 3, pp. 489-497, 1986.
181. X.-K. Zhang, I. Takashima, F. Mori, and N. Hashimoto, Comparison of virulence between two strains of Rattus serotype hemorrhagic fever with renal syndrome (HFRS) virus in newborn rats Microbiology and Immunology, vol. 33, no. 3, pp. 195-205, 1989.
182. T. Yamanouchi, K. Domae, O. Tanishita et al., Experimental infection in newborn mice and rats by hemorrhagic fever with renal syndrome (HFRS) virus Microbiology and Immunology, vol. 28, no. 12, pp. 1345-1353, 1984.
183. K. Araki, K. Yoshimatsu, B.-H. Lee, H. Kariwa, I. Takashima, and J. Arikawa, A new model of Hantaan virus persistence in mice: the balance between HTNV infection and CD8+ T-cell responses Virology, vol. 322, no. 2, pp. 318-327, 2004.
184. T. Kurata, T. F. Tsai, S. P. Bauer, and J. B. McCormick, Immunofluorescence studies of disseminated Hantaan virus infection of suckling mice Infection and Immunity, vol. 41, no. 1, pp. 391-398, 1983.
185. T. F. Tsai, S. Bauer, J. B. McCormick, and T. Kurata, Intracerebral inoculation of suckling mice with Hantaan virus The Lancet, vol. 320, no. 8296, pp. 503-504, 1982.
186. M. Tamura, H. Asada, K. Kondo, O. Tanishita, T. Kurata, and K. Yamanishi, Pathogenesis ofHantaan virus in mice TheJournal of General Virology, vol. 70, part 11, pp. 2897-2906, 1989.
187. H. W. Lee, P. W. Lee, L. J. Baek, C. K. Song, and I.W. Seong, Intraspecific transmission of Hantaan virus, etiologic agent of Korean hemorrhagic fever, in the rodent Apodemus agrarius TheAmerican Journal of Tropical Medicine andHygiene, vol. 30, no. 5, pp. 1106-1112, 1981.
188. J.W.Hooper,D.M. Custer, E.Thompson, and C. S. Schmaljohn, DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys Journal of Virology, vol. 75, no. 18, pp. 8469-8477, 2001.
189. C. S. Schmaljohn, Y.-K. Chu, A. L. Schmaljohn, and J. M. Dalrymple, Antigenic subunits of hantaan virus expressed by baculovirus and vaccinia virus recombinants Journal of Virology, vol. 64, no. 7, pp. 3162-3170, 1990.
190. Y.-K. Chu, G. B. Jennings, and C. S. Schmaljohn, A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus Journal of Virology, vol. 69, no. 10, pp. 6417-6423, 1995.
191. R. Yanagihara, H. L. Amyx, and D. C. Gajdusek, Experimental infection with Puumala virus, the etiologic agent of nephropathia epidemica, in bank voles (Clethrionomys glareolus) Journal of Virology, vol. 55, no. 1, pp. 34-38, 1985.
192. J. Groen,M. Gerding, J. P. Koeman et al., A macaquemodel for hantavirus infection The Journal of Infectious Diseases, vol. 172, no. 1, pp. 38-44, 1995.
193. J. Klingstrom, J. Hardestam, and A. Lundkvist, Dobrava, but not Saaremaa, hantavirus is lethal and induces nitric oxide production in suckling mice Microbes and Infection, vol. 8, no. 3, pp. 728-737, 2006.
194. S. R. Compton, R. O. Jacoby, F. X. Paturzo, and A. L. Smith, Persistent Seoul virus infection in Lewis rats Archives of Virology, vol. 149, no. 7, pp. 1325-1339, 2004.
195. S. L. Klein, B. H. Bird, and G. E. Glass, Sex differences in Seoul virus infection are not related to adult sex steroid concentrations in Norway rats Journal of Virology, vol. 74, no. 17, pp. 8213-8217, 2000.
196. J. W. Hooper, K. I. Kamrud, F. Elgh, D. Custer, and C. S. Schmaljohn, DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against Seoul virus infection Virology, vol. 255, no. 2, pp. 269-278, 1999.
197. J. W. Hooper, T. Larsen, D. M. Custer, and C. S. Schmaljohn, A lethal disease model for hantavirus pulmonary syndrome Virology, vol. 289, no. 1, pp. 6-14, 2001.
198. D. Safronetz, M. Zivcec, R. LaCasse et al., Pathogenesis and host response in syrian hamsters following intranasal infection with Andes virus PLoS Pathogens, vol. 7, no. 12, Article ID e1002426, 2011.
199. V.Wahl-Jensen, J. Chapman, L. Asher et al., Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters Journal of Virology, vol. 81, no. 14, pp. 7449-7462, 2007.
200. D. Safronetz, J. Prescott, E.Haddock, D. P. Scott, H. Feldmann, and H. Ebihara, Hamster-adapted Sin Nombre virus causes disseminated infection and efficiently replicates in pulmonary endothelial cells without signs of disease Journal of Virology, vol. 87, no. 8, pp. 4778-4782, 2013.
201. R. L. Brocato, C. D. Hammerbeck, T.M. Bell, J. B. Wells, L. A. Queen, and J.W.Hooper, A lethal diseasemodel for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with sin nombre virus Journal of Virology, vol. 88, no. 2, pp. 811-819, 2014.
202. D. Safronetz, J. Prescott, F. Feldmann et al., Pathophysiology of hantavirus pulmonary syndrome in rhesusmacaques Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 19, pp. 7114-7119, 2014.
203. J. Botten, K. Mirowsky, D. Kusewitt et al., Experimental infection model for sin nombre hantavirus in the deer mouse (Peromyscusmaniculatus) Proceedings of theNationalAcademy of Sciences of the United States of America, vol. 97, no. 19, pp. 10578-10583, 2000.
204. T. Schountz, M. Ac͡na-Retamar, S. Feinstein et al., Kinetics of immune responses in deer mice experimentally infected with sin Nombre virus Journal of Virology, vol. 86, no. 18, pp. 10015-10027, 2012.
205. M. L.Milazzo, E. J. Eyzaguirre, C. P.Molina, and C. F. Fulhorst, Maporal viral infection in the syrian golden hamster: a model of hantavirus pulmonary syndrome The Journal of Infectious Diseases, vol. 186, no. 10, pp. 1390-1395, 2002.
206. R. Yanagihara, H. L. Amyx, P.-W. Lee, D. M. Asher, C. J. Gibbs Jr., and D. C. Gajdusek, Experimental hantavirus infection in nonhuman primates Archives of Virology, vol. 101, no. 1-2, pp. 125-130, 1988.
207. R. Yanagihara, A. Svedmyr, H. L. Amyx et al., Isolation and propagation of nephropathia epidemica virus in bank voles Scandinavian Journal of Infectious Diseases, vol. 16, no. 3, pp. 225-228, 1984.
208. E. A. Tkachenko, V. N. Bashkirtsev, G. van der Groen, T. K. Dzagurova, A. P. Ivanov, and E. V. Ryltseva, Isolation in Vero-E6 cells of Hanta virus from Clethrionomys glareolus captured in the Bashkiria area of the U.S.S.R. Annales de la Societe Belge de Medecine Tropicale, vol. 64, no. 4, pp. 425-426, 1984.
209. T. Avsic-Zupanc, S. Y. Xiao, R. Stojanovic, A. Gligic, G. van der Groen, and J. W. LeDuc, Characterization of Dobrava virus: a Hantavirus from Slovenia, Yugoslavia Journal of Medical Virology, vol. 38, no. 2, pp. 132-137, 1992.
210. H. W. Lee, L. J. Baek, and K. M. Johnson, Isolation of Hantaan virus, the etiologic agent of Korean hemorrhagic fever, from wild urban rats The Journal of Infectious Diseases, vol. 146, no. 5, pp. 638-644, 1982.
211. T. Kitamura, C. Morita, T. Komatsu et al., Isolation of virus causing hemorrhagic fever with renal syndrome (HFRS) through a cell culture system Japanese Journal of Medical Science and Biology, vol. 36, no. 1, pp. 17-25, 1983.
212. J. Toro, J. D. Vega, A. S. Khan et al., An outbreak of hantavirus pulmonary syndrome, Chile, 1997 Emerging Infectious Diseases, vol. 4, no. 4, pp. 687-694, 1998.
213. A. L. Schmaljohn, D. Li, D. L. Negley et al., Isolation and initial characterization of a newfound hantavirus from California Virology, vol. 206, no. 2, pp. 963-972, 1995.
214. P. W. Lee, H. L. Amyx, R. Yanagihara, D. C. Gajdusek, D. Goldgaber, and C. J. Gibbs Jr., Partial characterization of Prospect Hill virus isolated from meadow voles in the United States Journal of Infectious Diseases, vol. 152, no. 4, pp. 826-829, 1985.
215. D. Wichmann, H.-J. Grone, M. Frese et al., Hantaan virus infection causes an acute neurological disease that is fatal in adult laboratory mice Journal of Virology, vol. 76, no. 17, pp. 8890-8899, 2002.
216. K. Araki, K. Yoshimatsu, B. H. Lee, H. Kariwa, I. Takashima, and J. Arikawa, Hantavirus-specific CD8(+)-T-cell responses in newborn mice persistently infected with Hantaan virus Journal of Virology, vol. 77, no. 15, pp. 8408-8417, 2003.
217. M. Taruishi, K. Yoshimatsu, K. Araki et al., Analysis of the immune response of Hantaan virus nucleocapsid proteinspecific CD8+ T cells in mice Virology, vol. 365, no. 2, pp. 292-301, 2007.
218. Y. C. Yoo, K. Yoshimatsu, Y. Koike et al., Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine Vaccine, vol. 16, no. 2-3, pp. 216-224, 1998.
219. I. S. Ha, Y. Choi, Y. S. Park et al., Development of monoclonal antibodies againstHantaan virus nucleocapsid protein Clinical and Diagnostic Laboratory Immunology, vol. 2, no. 4, pp. 439-442, 1995.
220. M. Bharadwaj, C. R. Lyons, I. A. Wortman, and B. Hjelle, Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune responses in BALB/c mice Vaccine, vol. 17, no. 22, pp. 2836-2843, 1999.
221. D. Koletzki, R. Schirmbeck, A. Lundkvist, H. Meisel, D. H. Kruger, and R.Ulrich, DNAvaccination of micewith a plasmid encoding Puumala hantavirus nucleocapsid protein mimics the B-cell response induced by virus infection Journal of Biotechnology, vol. 84, no. 1, pp. 73-78, 2000.
222. G. Bucht, K. B. Sjolander, S. Eriksson, L. Lindgren, A. Lundkvist, and F. Elgh, Modifying the cellular transport of DNA-based vaccines alters theimmune response to hantavirus nucleocapsid protein Vaccine, vol. 19, no. 28-29, pp. 3820-3829, 2001.
223. Z. Xu, L.Wei, L.Wang, H.Wang, and S. Jiang, The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization Biochemical and Biophysical Research Communications, vol. 298, no. 4, pp. 552-558, 2002.
224. P. Johansson, T. Lindgren, M. Lundstrom, A. Holmstrom, F. Elgh, and G. Bucht, PCR-generated linear DNA fragments utilized as a hantavirus DNA vaccine Vaccine, vol. 20, no. 27-28, pp. 3379-3388, 2002.
225. Y. Choi, C.-J. Ahn, K.-M. Seong, M.-Y. Jung, and B.-Y. Ahn, Inactivated Hantaan virus vaccine derived from suspension culture of Vero cells Vaccine, vol. 21, no. 17-18, pp. 1867-1873, 2003.
226. A. Gedvilaite, A. Zvirbliene, J. Staniulis, K. Sasnauskas, D. H. Kruger, and R. Ulrich, Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirusderived virus-like particles induce a strong immune response in mice Viral Immunology, vol. 17, no. 1, pp. 51-68, 2004.
227. A. Geldmacher, M. Schmaler, D. H. Kruger, and R. Ulrich, Yeast-expressed hantavirus Dobrava nucleocapsid protein induces a strong, long-lasting, and highly cross-reactive immune response in mice Viral Immunology, vol. 17, no. 1, pp. 115-122, 2004.
228. L. Y. Zheng, L. Mou, S. Lin, R.M. Lu, and E. J. Luo, Enhancing DNA vaccine potency against hantavirus by co-administration of interleukin-12 expression vector as a genetic adjuvant Chinese Medical Journal, vol. 118, no. 4, pp. 313-319, 2005.
229. A. Geldmacher, D. Skrastina, G. Borisova et al., A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies Vaccine, vol. 23, no. 30, pp. 3973-3983, 2005.
230. G.-J. Woo, E.-Y. Chun, H. K. Keun, and W. Kim, Analysis of immune responses against nucleocapsid protein of theHantaan virus elicited by virus infection or DNA vaccination Journal of Microbiology, vol. 43, no. 6, pp. 537-545, 2005.
231. B.-H. Lee,K.Yoshimatsu, K. Araki, M. Okumura, I. Nakamura, and J. Arikawa, A pseudotype vesicular stomatitis virus containing Hantaan virus nvelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice Vaccine, vol. 24, no. 15, pp. 2928-2934, 2006.
232. M. Lindkvist, K. Lahti, B. Lilliehöok, A. Holmstrom, C. Ahlm, and G. Bucht, Cross-reactive immune responses in mice after genetic vaccination with cDNA encoding hantavirus nucleocapsid proteins Vaccine, vol. 25, no. 9, pp. 1690-1699, 2007.
233. Y. Xiong, Y. Yuan,M. Jia, B. Yu, and H.Huang, Stable expression of Hantavirus H8205 strain G1/IL-2 gene and immune protection of the fusion gene Journal of Huazhong University of Science and Technology. Medical Sciences, vol. 27, no. 2, pp. 124-127, 2007.
234. H. Hao, L. Xiu, Z. Zehua et al., Genetic immunization with Hantavirus vaccine combining expression of G2 glycoprotein and fused interleukin-2 Genetic Vaccines and Therapy, vol. 6, article 15, 2008.
235. D. Safronetz, N. R. Hegde, H. Ebihara et al., Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus Journal of Virology, vol. 83, no. 14, pp. 7285-7295, 2009.
236. C. Zhao, Y. Sun, Y. Zhao et al., Immunogenicity of a multiepitope DNA vaccine against hantavirus Human Vaccines and Immunotherapeutics, vol. 8, no. 2, pp. 208-215, 2012.
237. J.Klingstrom, I.Maljkovic, B. Zuber, E. Rollman, A. Kjerrstrom, and A. Lundkvist, Vaccination of C57/BL6 mice with Dobrava hantavirus nucleocapsid protein in Freunds adjuvant induced partial protection against challenge Vaccine, vol. 22, no. 29-30, pp. 4029-4034, 2004.
238. J. Li, Z. X. Ye, K. N. Li et al., HSP70 gene fused with Hantavirus S segment DNA significantly enhances the DNA vaccine potency against hantaviral nucleocapsid protein in vivo Vaccine, vol. 25, no. 2, pp. 239-252, 2007.
239. J. Li, K. N. Li, J. Gao, J. H. Cui, Y. F. Liu, and S. J. Yang, Heat shock protein 70 fused to or complexed with hantavirus nucleocapsid protein significantly enhances specific humoral and cellular immune responses in C57BL/6 mice Vaccine, vol. 26, no. 25, pp. 3175-3187, 2008.
240. S. Cao, Y. Zhang, F. Liu et al., Secretory expression and purification of recombinant escherichia coli heat-Labile enterotoxin B subunit and its applications on intranasal vaccination of hantavirus Molecular Biotechnology, vol. 41, no. 2, pp. 91-98, 2009.
241. C. Li, F. Liu, M. Liang et al., Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice Vaccine, vol. 28, no. 26, pp. 4294-4300, 2010.
242. P.-Y. Li, L. Yu, X.-A. Wu et al., Modification of the adenoviral transfer vector enhances expression of the Hantavirus fusion protein GnS0.7 and induces a strong immune response in C57BL/6 mice Journal of Virological Methods, vol. 179, no. 1, pp. 90-96, 2012.
243. F. Liu, M. Liang, S. Cao et al., Fusion with extracellular domain of cytotoxic T-lymphocyte-associated-antigen 4 leads to enhancement of immunogenicity of Hantaan virus DNA vaccines in C57BL/6 mice Virology Journal, vol. 8, article 448, 2011.
244. K. Li, P.-Y. Li, X.-A. Wu et al., Induction of Hantaan virusspecific immune responses in C57BL/6 mice by immunization with a modified recombinant adenovirus containing the chimeric gene, GcS0.7 International Journal of Molecular Medicine, vol. 32, no. 3, pp. 709-716, 2013.
245. L. Cheng, L. Yu, X. Wu et al., Induction of specific humoral and cellular immune responses in a mouse model following gene fusion of HSP70C and Hantaan virus Gn and S0.7 in an adenoviral vector PLoS ONE, vol. 9, no. 2, Article ID e88183, 2014.
246. L. Yu, W. Bai, X. Wu et al., A recombinant pseudotyped lentivirus expressing the envelope glycoprotein of hantaan virus induced protective immunity in mice Virology Journal, vol. 10, article 301, 2013.
247. P. Maes, J. Clement, B. Cauwe et al., Truncated recombinant Puumala virus nucleocapsid proteins protect mice against challenge in vivo Viral Immunology, vol. 21, no. 1, pp. 49-60, 2008.
248. P. Maes, E. Keyaerts, V. Bonnet et al., Truncated recombinant dobrava hantavirus nucleocapsid proteins induce strong, longlasting immune responses in mice Intervirology, vol. 49, no. 5, pp. 253-260, 2006.
249. K. Maeda, K. West, D. Hayasaka, F. A. Ennis, and M. Terajima, Recombinant adenovirus vector vaccine induces stronger cytotoxic T-cell responses than recombinant vaccinia virus vector, plasmid DNA, or a combination of these Viral Immunology, vol. 18, no. 4, pp. 657-667, 2005.
250. M. Bharadwaj, K.Mirowsky, C. Ye et al., Genetic vaccines protect against Sin Nombre hantavirus challenge in the deer mouse (Peromyscus maniculatus)The Journal of GeneralVirology, vol. 83, no. 7, pp. 1745-1751, 2002.
251. A. A. Rizvanov, A. G. M. van Geelen, S. Morzunov et al., Generation of a recombinant cytomegalovirus for expression of a hantavirus glycoprotein Journal of Virology, vol. 77, no. 22, pp. 12203-12210, 2003.
252. K. Yoshimatsu, J. Arikawa, S. Ohbora, and C. Itakura, Hantavirus Infection in SCID Mice The Journal of Veterinary Medical Science, vol. 59, no. 10, pp. 863-868, 1997.
253. T. Koma, K. Yoshimatsu, N. Nagata et al., Neutrophil depletion suppresses pulmonary vascular hyperpermeability and occurrence of pulmonary edema caused by hantavirus infection in C.B-17 SCID mice Journal of Virology, vol. 88, no. 13, pp. 7178-7188, 2014.
254. K. Araki, K. Yoshimatsu, B.-H. Lee et al., Age-dependent hantavirus-specific CD8+ T-cell responses in mice infectedwith Hantaan virus Archives of Virology, vol. 149, no. 7, pp. 1373-1382, 2004.
255. T. Sanada, H. Kariwa, N. Nagata et al., Puumala virus infection in Syrian hamsters (Mesocricetus auratus) resembling hantavirus infection in natural rodent hosts Virus Research, vol. 160, no. 1-2, pp. 108-119, 2011.
256. K. I. Kamrud, J. W. Hooper, F. Elgh, and C. S. Schmaljohn, Comparison of the protective efficacy of naked DNA, DNAbased sindbis replicon, and packaged sindbis replicon vectors expressing Hantavirus structural genes in hamsters Virology, vol. 263, no. 1, pp. 209-219, 1999.
257. M. Liang, Y.-K. Chu, and C. Schmaljohn, Bacterial expression of neutralizing mouse monoclonal antibody Fab fragments to Hantaan virus Virology, vol. 217, no. 1, pp. 262-271, 1996.
258. K. Hardcastle, D. Scott, D. Safronetz et al., Laguna Negra virus infection causes Hantavirus pulmonary syndrome in Turkish hamsters (Mesocricetus brandti) Veterinary Pathology, 2015.
259. C. D. Hammerbeck and J.W.Hooper, T Cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome Journal of Virology, vol. 85, no. 19, pp. 9929-9944, 2011.
260. K. S. Brown, D. Safronetz, A. Marzi, H. Ebihara, and H. Feldmann, Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with andes virus Journal of Virology, vol. 85, no. 23, pp. 12781-12791, 2011.
261. J. Prescott, B. L. DeBuysscher, K. S. Brown, and H. Feldmann, Long-term single-dose efficacy of a vesicular Stomatitis virusbased Andes virus vaccine in Syrian hamsters Viruses, vol. 6, no. 2, pp. 516-523, 2014.
262. D.M.Custer, E.Thompson, C. S. Schmaljohn, T. G. Ksiazek, and J.W.Hooper, Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segmentbased DNA vaccine Journal of Virology, vol. 77, no. 18, pp. 9894-9905, 2003.
263. K.W. Spik,C.Badger, I. Mathiessen, T. Tjelle, J.W.Hooper, and C. Schmaljohn, Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters Vaccine, vol. 26, no. 40, pp. 5177-5181, 2008.
264. R. L. Brocato, M. J. Josleyn, V. Wahl-Jensen, C. S. Schmaljohn, and J. W. Hooper, Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine Clinical and Vaccine Immunology, vol. 20, no. 2, pp. 218-226, 2013.
265. R. Brocato, M. Josleyn, J. Ballantyne, P. Vial, and J. W. Hooper, DNAvaccine-generated duck polyclonal antibodies asa postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS) PLoS ONE, vol. 7, no. 4, Article ID e35996, 2012.
266. J. W. Hooper, R. L. Brocato, S. A. Kwilas et al., DNA vaccinederived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome Science Translational Medicine, vol. 6, no. 264, Article ID 264ra162, 2014.
267. J. W. Hooper, D. M. Custer, J. Smith, and V. Wahl-Jensen, Hantaan/Andes virus DNA vaccine elicits a broadly crossreactive neutralizing antibody response in nonhuman primates Virology, vol. 347, no. 1, pp. 208-216, 2006.
268. P. A. Vial, F. Valdivieso, M. Calvo et al., A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome by ANDV Antiviral Therapy, 2014.
269. C. B. Jonsson, J.Hooper, and G.Mertz, Treatment of hantavirus pulmonary syndrome Antiviral Research, vol. 78,no. 1, pp. 162-169, 2008.
270. R. C. McDermid, R. T. N. Gibney, R. J. Brisebois, and N. M. Skjodt, Drotrecogin alpha (activated) in two patients with the hantavirus cardiopulmonary syndrome Canadian Respiratory Journal, vol. 13, no. 5, pp. 272-274, 2006.
271. M. Ogg, C. B. Jonsson, J. V. Camp, and J. W. Hooper, Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome-after intranasal exposure to andes virus Viruses, vol. 5, no. 11, pp. 2704-2720, 2013.
272. D. Safronetz, D. Falzarano, D. P. Scott, Y. Furuta,H. Feldmann, and B. B. Gowen, Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome Antimicrobial Agents and Chemotherapy, vol. 57, no. 10, pp. 4673-4680, 2013.
273. D. Safronetz, E. Haddock, F. Feldmann, H. Ebihara, and H. Feldmann, In vitro and in vivo activity of Ribavirin against Andes virus infection PLoS ONE, vol. 6, no. 8, Article ID e23560, 2011.
274. J. Prescott,D. Safronetz, E.Haddock, S. Robertson,D. Scott, and H. Feldmann, The adaptive immune response does not influence hantavirus disease or persistence in the syrian hamster Immunology, vol. 140, no. 2, pp. 168-178, 2013.
275. L. B. Chen andW. S. Yang, Abnormalities of T cell immunoregulation in hemorrhagic fever with renal syndrome The Journal of Infectious Diseases, vol. 161, no. 5, pp. 1016-1019, 1990.
276. S. Gupta, M. Braun, N. D. Tischler et al., Hantavirus-infection confers resistance to cytotoxic lymphocyte-mediated apoptosis PLoS Pathogens, vol. 9, no. 3,Article ID e1003272, 2013.
277. N. Tchitchek, D. Safronetz, A. L. Rasmussen et al., Sequencing, annotation and analysis of the Syrian hamster (Mesocricetus auratus) transcriptome PLoS ONE, vol. 9, no. 11, Article ID e112617, 2014.
278. J. Klingstrom, P. Heyman, S. Escutenaire et al., Rodent host specificity of european hantaviruses: evidence of Puumala virus interspecific spillover Journal of Medical Virology, vol. 68, no. 4, pp. 581-588, 2002.
279. W.-P. Guo, X.-D. Lin,W.Wang et al., Phylogeny and origins of hantaviruses harbored by bats, insectivores, and rodents PLoS Pathogens, vol. 9, no. 2,Article ID e1003159, 2013.
280. C. H. Calisher, J. E. Childs, H. E. Field, K. V. Holmes, and T. Schountz, Bats: important reservoir hosts of emerging viruses Clinical Microbiology Reviews, vol. 19, no. 3, pp. 531-545, 2006.
281. J. Botten, K. Mirowsky, D. Kusewitt et al., Persistent Sin Nombre virus infection in the deermouse (Peromyscusmaniculatus) model: sites of replication and strand-specific expression Journal of Virology, vol. 77, no. 2, pp. 1540-1550, 2003.
282. T. Schountz, S. Quackenbush, J. Rovnak et al., Differential lymphocyte and antibody responses in deer mice infected with Sin Nombre hantavirus or Andes hantavirus Journal of Virology, vol. 88, no. 15, pp. 8319-8331, 2014.
283. J. R. Spengler, E.Haddock, D. Gardner, B. Hjelle,H. Feldmann, and J. Prescott, Experimental Andes virus infection in deer mice: characteristics of infection and clearance in a heterologous rodent host PLoS ONE, vol. 8, no. 1, Article ID e55310, 2013.
284. H. Kariwa, M. Kimura, S. Yoshizumi et al., Modes of Seoul virus infections: persistency in newborn rats and transiency in adult rats Archives of Virology, vol. 141, no. 12, pp. 2327-2338, 1996.
285. J. D. Easterbrook and S. L. Klein, Seoul virus enhances regulatory and reduces proinflammatory responses in male Norway rats Journal of Medical Virology, vol. 80, no. 7, pp. 1308-1318, 2008.
286. M. F.Hannah, V. B. Bajic, and S. L. Klein, Sex differences in the recognition of and innate antiviral responses to Seoul virus in Norway rats Brain, Behavior, and Immunity, vol. 22, no. 4, pp. 503-516, 2008.
287. S. L. Klein, A. Cernetich, S. Hilmer, E. P. Hoffman, A. L. Scott, and G. E. Glass, Differential expression of immunoregulatory genes in male and female Norway rats following infection with Seoul virus Journal of Medical Virology, vol. 74, no. 1, pp. 180-190, 2004.
288. T. Schountz and J. Prescott, Hantavirus immunology of rodent reservoirs: current status and future directions Viruses, vol. 6, no. 3, pp. 1317-1335, 2014.
289. A. K. McElroy, M. Bray, D. S. Reed, and C. S. Schmaljohn, Andes virus infection of cynomolgus macaques The Journal of Infectious Diseases, vol. 186, no. 12, pp. 1706-1712, 2002.
290. J. Klingstrom, A. Plyusnin, A. Vaheri, and A. Lundkvist, Wild-type Puumala hantavirus infection induces cytokines, C-reactive protein, creatinine, and nitric oxide in cynomolgus macaques Journal of Virology, vol. 76, no. 1, pp. 444-449, 2002.
291. T. Sironen, J. Klingstrom, A. Vaheri, L. C. Andersson, A. Lundkvist, and A. Plyusnin, Pathology of Puumala hantavirus infection in Macaques PLoS ONE, vol. 3, no. 8, Article ID e3035, 2008.
292. J. Klingstrom, K. I. Falk, and A. Lundkvist, Delayed viremia and antibody responses in Puumala hantavirus challenged passively immunized cynomolgus macaques Archives of Virology, vol. 150, no. 1, pp. 79-92, 2005.
293. J. Klingstrom, M. Stoltz, J. Hardestam, C. Ahlm, and A. Lundkvist, Passive immunization protects cynomolgus macaques against Puumala hantavirus challenge Antiviral Therapy, vol. 13, no. 1, pp. 125-133, 2008.
294. M. G. Kortepeter, T. J. Cieslak, and E.M. Eitzen, Bioterrorism Journal of Environmental Health, vol. 63, no. 6, pp. 21-24, 2001.
295. S. R. Samoilovich, G. Carballal, and M. C. Weissenbacher, Protection against a pathogenic strain of Junin virus by mucosal infection with an attenuated strain The American Journal of TropicalMedicine and Hygiene, vol. 32, no. 4, pp. 825-828, 1983.
296. J. R. Oubina and G. Carballal, Neurotropism of a high-passage XJ strain of Junin virus Journal ofMedical Virology, vol. 15, no. 2, pp. 157-161, 1985.
297. E. Bergeron, A. K. Chakrabarti, B. H. Bird et al., Reverse genetics recovery of Lujo virus and role of virus RNA secondary structures in efficient virus growth Journal of Virology, vol. 86, no. 19, pp. 10759-10765, 2012.
298. P. J. Snoy, Establishing efficacy of human products using animals: the US food and drug administrations animal rulea Veterinary Pathology, vol. 47, no. 5, pp. 774-778, 2010.
299. R. Mercado, Rodent control programmes in areas affected by Bolivian haemorrhagic fever Bulletin of the World Health Organization, vol. 52, no. 4-5, pp. 691-696, 1975.
300. R. A. Keenlyside, J. B. McCormick, P. A. Webb, E. Smith, L. Elliott, and K. M. Johnson, Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone The American Journal of Tropical Medicine and Hygiene, vol. 32, no. 4, pp. 829-837, 1983.
301. M. Mateo, C. Carbonnelle, O. Reynard et al., VP24 is a molecular determinant of Ebola virus virulence in Guinea pigs The Journal of Infectious Diseases, vol. 204, supplement 3, pp. S1011-S1020, 2011.
302. J. J. N͡nez, C. L. Fritz, B. Knust et al., Hantavirus infections among overnight visitors to YosemiteNational Park, California, USA, 2012 Emerging Infectious Diseases, vol. 20, no. 3, pp. 386-393, 2014.